BioAtla (BCAB) Consolidated Net Income (2020 - 2026)
BioAtla's (BCAB) quarterly Consolidated Net Income came in at $232000.0 in Q2 2026, up 101.26% on a YoY basis from $115273.8 in Q2 2025, and up 102.5% quarter-over-quarter from -$9.3 million in Q1 2026.
Analysis
BioAtla (BCAB) Consolidated Net Income (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Consolidated Net Income for 7 consecutive years, with $232000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Consolidated Net Income rose 101.26% year-over-year to $232000.0; the trailing twelve-month figure through Jun 2026 stood at -$31.9 million (up 48.47% YoY), and the FY2025 full-year result was -$58.5 million, up 17.16% from the prior year.
- Consolidated Net Income grew to $232000.0 in Q2 2026 per BCAB's latest filing, from -$9.3 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at $232000.0 in Q2 2026 and bottomed at -$35.7 million in Q2 2023.
- Historically, Consolidated Net Income has averaged -$20.4 million across 5 years, with a median of -$22.2 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Consolidated Net Income retreated 29.73% in 2022, then jumped 101.26% in 2026.
- Over 5 years, Consolidated Net Income stood at -$27.5 million in 2022, then rose by 2.24% to -$26.9 million in 2023, then soared by 41.67% to -$15.7 million in 2024, then surged by 41.48% to -$9.2 million in 2025, then soared by 102.53% to $232000.0 in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered $232000.0, -$9.3 million, and -$9.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 232,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 232,000.00 |
| Mar 31, 2026 | -9.29 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -13.66 Mn |
| Jun 30, 2025 | -18.41 Mn |
| Mar 31, 2025 | -17.21 Mn |
| Dec 31, 2024 | -15.69 Mn |
| Sep 30, 2024 | -10.59 Mn |
| Jun 30, 2024 | -21.07 Mn |
| Mar 31, 2024 | -23.23 Mn |
| Dec 31, 2023 | -26.90 Mn |
| Sep 30, 2023 | -33.29 Mn |
| Jun 30, 2023 | -35.74 Mn |
| Mar 31, 2023 | -27.45 Mn |
| Dec 31, 2022 | -27.51 Mn |
| Sep 30, 2022 | -25.81 Mn |
| Jun 30, 2022 | -28.91 Mn |
| Mar 31, 2022 | -24.26 Mn |
| Dec 31, 2021 | -23.39 Mn |
| Sep 30, 2021 | -23.62 Mn |